Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 7244826
Internalizing ERB2 antibodies
granted -
US 7241867
Polypeptide encoded by a nucleotide sequence of a nontypeable strain of Haemophilus influenzae genome
granted -
US 7241746
Method and composition for treating periodontal disease
granted -
US 7241571
Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
granted -
US 7238366
Submicron liposome suspensions obtained from preliposome lyophilizates
granted -
US 7238489
Identification of sortase gene
granted -
US 7238369
Cationic liposome delivery of taxanes to angiogenic blood vessels
granted -
US 7238673
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
granted -
US 7238800
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
granted -
US 7238708
Glucose sensor
granted -
US 7238525
Strategy for leukemia therapy
granted -
US 7238475
Apolipoprotein gene involved in lipid metabolism
granted -
US 7235529
Brain-associated inhibitor of tissue-type plasminogen activator
granted -
US 7235236
Polynucleotide encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function
granted -
US 7235573
Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
granted -
US 7235577
Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
granted -
US 7232684
DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
granted -
US 7232570
ERAAP modulators regulate immune responses
granted -
US 7229604
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
granted -
US 7229826
Process for ex vivo formation of mammalian bone and uses thereof
granted -
US 7230086
Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices
granted -
US 7229628
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
granted -
US 7229770
YKL-40 as a marker and prognostic indicator for cancers
granted -
US 7226937
Methods for modulating phototoxicity
granted -
US 7226597
Mutants of Clostridium difficile toxin B and methods of use
granted -
US 7226609
Sodium dodecyl sulfate compositions for inactivating prions
granted -
US 7226588
Non-toxic mutants of pathogenic gram-negative bacteria
granted -
US 7226589
Treatment of diseases by site specific instillation of cells or site specific transformation of cells and kits therefor
granted -
US 7223380
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
granted -
US 7223726
Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
granted -
US 7223571
Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
granted -
US 7223388
Modified reoviral therapy
granted -
US 7223787
Prenylation inhibitors reduce host cell permissiveness to viral replication
granted -
US 7223406
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
granted -
US 7220726
Antifungal pimaricin compositions and therapeutic methods employing same
granted -
US 7220739
Therapeutic application of pro-apoptotic benzodiazepines
granted -
US 7220431
Methods and compositions for applying pharmacologic agents to the ear
granted -
US 7220853
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1
granted -
US 7220837
Modified vitamin K-dependent polypeptides
granted -
US 7220730
Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer
granted -
US 7220421
Moraxella bovis cytotoxin, cytotoxin gene, antibodies and vaccines for prevention and treatment of Moraxella bovis infections
granted -
US 7217571
Gene therapy by small fragment homologous replacement
granted -
US 7217785
Cysteine-containing peptides having antioxidant properties
granted -
US 7217795
Tumor suppressor designated TS10q23.3
granted -
US 7217739
Method for inducing cell death with carbonyl scavengers
granted -
US 7217427
Polymersomes and related encapsulating membranes
granted -
US 7214512
Genomic mammary Amyloid a sequence
granted -
US 7214519
Screening method for identifying heme independent modulators of soluble guanylyl cyclase (sGC) activity using Ξ±Ξ²Cys105 mutant sGC
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory